Author

Ian P. Street

UNSW SydneyORCID 0000-0003-2684-4239Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Alice SalibiD· 1 shared Andrea GillespieiD· 1 shared Anelya MuratiD· 1 shared Antoine de WeckiD· 1 shared Benjamin J. BlythiD· 1 shared Brendon J. MonahaniD· 1 shared Chelsea MayohiD· 1 shared Dane VassiliadisiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alice SalibORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintOct 21, 2026

METTL1 gene dosage and catalytic activity define a targetable vulnerability in pediatric cancers

Pei Yan Liu, Steven He, Olesya O. Panasenko…·Paul G. Ekert

This study identifies METTL1 gene dosage and catalytic activity as therapeutic targets in pediatric cancers, showing that inhibiting METTL1 synergizes with BCL-xL inhibitors.

DOI 10.64898/2026.10.20.760582

humanexperimental assay

𝕏 PostBluesky

Cancer BiologyCancer DiscoveryPeer-reviewedJun 19, 2025

Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia

Shellaina J.V. Gordon, Florian Perner, Laura MacPherson…·Mark A. Dawson

The paper shows that inhibiting KAT6/KAT7 enhances Menin inhibitor efficacy and overcomes resistance in MLL-FP leukemia.

31 citationstop 1%

humanexperimental assay

𝕏 PostBluesky